Molecular Pathology of
Esophageal Cancer
Esophageal Cancer
|
Molecular Pathology of Esophageal Cancer |
| Home | • | About | • | Our Team | • | Expert Opinion | • | CuraBase Workspace | • | Contact |
|
| Region | Incidence Overall | Incidence Males | Incidence Females | Deaths Overall | Deaths Males | Deaths Females |
|---|---|---|---|---|---|---|
| USA | 16640 | 13130 | 3510 | 14500 | 11650 | 2850 |
| Affected Protein | Pathway | Sub-Type | Ethnicity | Stage | Frequency (%) | Gene Amplification | Activating Mutation | Inactivating Mutation | Deletion | Promoter Hypermethylation | Comment | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APC (adenomatosis polyposis coli) | WNT Signaling |
EAC | 68-92% | |||||||||
| APC (adenomatosis polyposis coli) | WNT Signaling |
SCC | 50% | |||||||||
| BRAF | Ras Signal Transduction Pathway |
Adenocarcinoma | 11% | |||||||||
| C-Myc | Cell Cycle Regulation |
EAC (esophageal adenocarcinoma) | 25% | |||||||||
| C2orf40 (ECRG4) | SCC | 80% | ||||||||||
| CADM1 (TSLC1) | Cell-cell adhesion |
SCC | 50% | loss of expression | ||||||||
| CHFR | SCC and EAC | 16% | ||||||||||
| DAPK (Death-Associated Protein Kinase) | Apoptosis regulation |
78% | ||||||||||
| E-Cadherin (CDH1) | Cell-cell adhesion |
EAC and SCC, respectively | 66-84% and 80% | |||||||||
| EGFR (ErbB-1 receptor) | Receptor Tyrosine Kinase Signaling |
EAC | 19% | |||||||||
| ErbB-2 (Her2/neu) | Receptor Tyrosine Kinase Signaling |
squamous cell carcinoma | 19% | |||||||||
| ESR1 (Estrogen receptor alpha) | EAC | 51% | ||||||||||
| EYA4 | EAC | 83% | ||||||||||
| H-cadherin (CDH13) | Cell-cell adhesion |
SCC + EAC | 14% | |||||||||
| HLA-C (HLA class I) | SCC | 45% | ||||||||||
| KRAS | Ras Signal Transduction Pathway |
Adenocarcinoma | 21% | |||||||||
| MDM2 | p53 Tumor Suppressor Pathway |
esophageal carcinoma | 13 - 18% | |||||||||
| MGMT | DNA-Repair |
SCC and EAC, respectively | 39 and 56% | |||||||||
| p14ARF (CDKN2A) | p53 Tumor Suppressor Pathway |
SCC | 33% | |||||||||
| p14ARF (CDKN2A) | p53 Tumor Suppressor Pathway |
SCC | 15% | not found in EAC | ||||||||
| p15INK4b (CDKN2B) | Cell Cycle Regulation |
SCC | 40% | |||||||||
| p15INK4b (CDKN2B) | Cell Cycle Regulation |
SCC | 13-18% | |||||||||
| p16INK4a (CDKN2A) | Cell Cycle Regulation |
esophageal adenocarcinoma (EAC) | 39-54% | |||||||||
| p16INK4a (CDKN2A) | Cell Cycle Regulation |
SCC | 18% | |||||||||
| p16INK4a (CDKN2A) | Cell Cycle Regulation |
squamous cell carcinoma (SCC) | 40-64% | |||||||||
| p53 | p53 Tumor Suppressor Pathway |
30 % | ||||||||||
| RARbeta (retinoid acid receptor, beta) | Transcriptional regulation |
SCC | 70% | |||||||||
| RASSF1A (Ras-association domain family 1) | Cell Cycle Regulation |
primary SCC | 34-51% | |||||||||
| RB1 | Cell Cycle Regulation |
EAC | 33% | |||||||||
| SFRP1 (secreted frizzled related protein 1) | WNT Signaling |
EAC | 93% | |||||||||
| TIMP3 | EAC | 19 - 90% | ||||||||||
| UCHL1 (PGP9.5) | SCC | 42% | ||||||||||
| VHL | Protein Degradation |
SCC | 13% |
| See Clinical Trials in in the TTC Database |
| CANCER.GOV PDQ® - Standard Treatments for Esophageal Cancer |